证券之星消息，截至2025年12月30日收盘，美好医疗(301363)报收于25.0元，下跌0.16%，换手率 3.12%，成交量11.64万手，成交额2.87亿元。 12月30日的资金流向数据方面，主力资金净流入3572.97万元，占总成交额12.44%，游资资金净流入 405.48万元，占总成交额1.41%，散户资金净流出3978.45万元，占总成交额13.85%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-30 | 25.00 -0.16% | | 3572.97万 | 12.44% | 405.48万 | 1.41% | -3978.45万 | -13.85% | | 2025-12-29 | 25.04 | 8.30% | 5430.43万 | 11.28% | -4672.75万 | -9.70% | -757.68万 | -1.57% | | 2025-12- ...

12月5日的资金流向数据方面，主力资金净流出933.9万元，占总成交额9.2%，游资资金净流入386.11万 元，占总成交额3.81%，散户资金净流入547.79万元，占总成交额5.4%。 证券之星消息，截至2025年12月5日收盘，美好医疗(301363)报收于21.42元，下跌0.46%，换手率 1.27%，成交量4.75万手，成交额1.01亿元。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：为全球医疗器械企业提供从产品设计开发到批量生产交付的 全流程一站式服务。 该股最近90天内共有13家机构给出评级，买入评级11家，增持评级2家；过去90天内机构目标均 ...

证券之星消息，截至2025年12月2日收盘，美好医疗(301363)报收于21.21元，上涨0.09%，换手率 0.72%，成交量2.7万手，成交额5676.04万元。 12月2日的资金流向数据方面，主力资金净流出200.72万元，占总成交额3.54%，游资资金净流入260.69 万元，占总成交额4.59%，散户资金净流出59.96万元，占总成交额1.06%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-02 | 21.21 0.09% | | -200.72万 | -3.54% | 260.69万 | 4.59% | -59.96万 | -1.06% | | 2025-12-01 | 21.19 -0.19% | | -232.84万 | -3.84% | -20.18万 | -0.33% | 253.02万 | 4.17% | | 2025-11-28 | 21.23 0 ...

Core Viewpoint - The stock of Meihao Medical (301363) has shown fluctuations in trading volume and capital flow, with a slight increase in share price on November 27, 2025, despite net outflows from major and retail investors [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, an increase of 5.89% year-on-year [3]. - The company's gross profit margin stands at 39.34%, with a net profit margin of 17.43% [3]. Market Position - Meihao Medical's total market capitalization is 11.997 billion yuan, which is higher than the industry average of 11.026 billion yuan, ranking 25th out of 124 in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 43.22, which is lower than the industry average of 56.75, ranking 48th out of 124 [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd out of 124 [3]. Investor Sentiment - Over the past 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating positive sentiment among analysts [4]. - The average target price set by institutions for the stock is 25.2 yuan [4].

Core Viewpoint - The stock of Meihao Medical (301363) has shown fluctuations in trading performance, with a recent closing price of 20.83 yuan, reflecting a 2.51% increase on November 24, 2025, amidst varying capital flows [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decline of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.9 million yuan, an increase of 5.89% year-on-year [3]. Capital Flow Analysis - On November 24, 2025, the net outflow of main funds was 4.29 million yuan, accounting for 4.82% of the total transaction amount, while retail investors saw a net inflow of 9.61 million yuan, representing 10.78% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced varying capital flows, with significant net outflows from main and speculative funds on several days [2]. Industry Comparison - Meihao Medical's total market value stands at 11.85 billion yuan, slightly above the industry average of 10.978 billion yuan, ranking 25th out of 124 in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) is 42.69, which is lower than the industry average of 55.96, ranking 50th in the industry [3]. Analyst Ratings - In the last 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating a generally positive outlook [4].

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 20.32 yuan on November 21, 2025, down 3.79% from the previous day, indicating a negative trend in recent trading activity [1]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, a year-on-year increase of 3.28% [3]. - The net profit attributable to shareholders was 208 million yuan, a year-on-year decrease of 19.25% [3]. - The third quarter of 2025 saw a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, up 5.89% year-on-year [3]. - The company’s gross profit margin stands at 39.34%, which is lower than the industry average of 51.22% [3]. Market Position and Valuation - Meihao Medical has a total market capitalization of 11.559 billion yuan, ranking 26th in the medical device industry [3]. - The company’s price-to-earnings ratio (P/E) is 41.64, which is lower than the industry average of 54.54, ranking 49th [3]. - The price-to-book ratio (P/B) is 3.12, compared to the industry average of 3.77, ranking 78th [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd [3]. Recent Trading Activity - On November 21, 2025, the net outflow of main funds was 5.339 million yuan, accounting for 6.37% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuations in fund flows, with notable net inflows and outflows from different investor categories [2]. - The average target price set by 14 institutions over the past 90 days is 25.2 yuan, with 12 buy ratings and 2 hold ratings [4].

证券之星消息，截至2025年11月19日收盘，美好医疗(301363)报收于20.99元，下跌1.13%，换手率 0.74%，成交量2.77万手，成交额5835.49万元。 11月19日的资金流向数据方面，主力资金净流出825.82万元，占总成交额14.15%，游资资金净流入 12.79万元，占总成交额0.22%，散户资金净流入813.03万元，占总成交额13.93%。 近5日资金流向一览见下表： | 指标 | 美好医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 119.41亿元 | 112.79亿元 | 27 124 | | 净资产 | 37.02亿元 | 38.93亿元 | 41 124 | | 净利润 | 2.08亿元 | 2.12亿元 | 27 124 | | 市盈率(动) | 43.01 | 56.7 | 49 124 | | 市净率 | 3.23 | 3.97 | 76 124 | | 毛利率 | 39.34% | 51.22% | 88 124 | | 净利率 | 17.43% | 9.57% | 42 124 | | ROE | ...

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with significant fluctuations in capital flow, indicating mixed investor sentiment and potential opportunities for analysis [1][2]. Group 1: Stock Performance - As of November 12, 2025, Meihao Medical's stock closed at 21.99 yuan, up by 0.92%, with a turnover rate of 1.32% and a trading volume of 49,100 hands, resulting in a transaction amount of 108 million yuan [1]. - Over the past five days, the stock has experienced varying capital flows, with a net inflow of 432.06 million yuan from main funds on November 12, representing 4.0% of the total transaction amount [2]. Group 2: Financial Metrics - Meihao Medical's total market value is 12.509 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan, ranking 27th in the medical device industry [3]. - The company's revenue for the first three quarters of 2025 was 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit decreased by 19.25% to 208 million yuan [3]. Group 3: Institutional Ratings - In the last 90 days, 18 institutions have rated Meihao Medical, with 16 buy ratings and 2 hold ratings, indicating a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - The stock of Meihai Medical (301363) has experienced a decline, with significant net outflows from major and retail investors, while the company shows mixed financial performance in recent reports [1][2][3]. Financial Performance - As of November 6, 2025, Meihai Medical's stock closed at 22.18 yuan, down 1.38% with a trading volume of 48,700 hands and a turnover of 107 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 4.62 billion yuan, a year-on-year increase of 2.56%, while the net profit attributable to shareholders was 93.90 million yuan, up 5.89% year-on-year [3]. - For the first three quarters of 2025, the company's main revenue was 11.94 billion yuan, a year-on-year increase of 3.28%, but the net profit decreased by 19.25% to 208 million yuan [3]. Market Position and Ratios - Meihai Medical's total market value is 12.618 billion yuan, with a net asset of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company has a price-to-earnings ratio (P/E) of 45.45, which is lower than the industry average of 62.24, indicating a relatively favorable valuation [3]. - The gross margin stands at 39.34%, significantly lower than the industry average of 51.22%, while the net margin is 17.43%, higher than the industry average of 9.57% [3]. Investor Sentiment - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings, indicating a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4]. Capital Flow Analysis - On November 6, 2025, the net outflow of major funds was 20.15 million yuan, accounting for 18.75% of the total turnover, while retail investors saw a net inflow of 24.06 million yuan, representing 22.39% of the total turnover [1][2].

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 22.89 yuan on November 4, 2025, down 2.35% from the previous day [1] Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year [3] - The net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [3] - The third quarter of 2025 saw a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, up 5.89% year-on-year [3] Market Activity - On November 4, 2025, the net outflow of main funds was 3.6489 million yuan, accounting for 4.48% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with significant net outflows from main funds on several days [2] Industry Comparison - Meihao Medical's total market value is 13.021 billion yuan, which is higher than the industry average of 11.456 billion yuan [3] - The company's price-to-earnings ratio (P/E) is 46.91, which is lower than the industry average of 60.95, indicating a relatively favorable valuation [3] - The gross profit margin of Meihao Medical is 39.34%, significantly lower than the industry average of 51.22% [3] Analyst Ratings - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings [4] - The average target price set by institutions over the past 90 days is 25.2 yuan [4]